Physician profile
Michael Gower
NPI 1265660104
$6,030.31
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $519 · 2022: $1,726 · 2023: $2,735 · 2024: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,786.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,068.42 | 2021-2024 | |
| Tris Pharma INC | $775.13 | 2022-2024 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $568.04 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $416.61 | 2021-2024 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $330.52 | 2022-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $309.10 | 2022-2024 | Jornay Pm |
| Alkermes, INC. | $303.07 | 2021-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $300.26 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $292.13 | 2021-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $229.03 | 2021-2024 | Ingrezza |
| Lundbeck LLC | $215.13 | 2021-2024 | Rexulti |
| Corium, LLC | $184.48 | 2022-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $157.49 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $151.83 | 2022-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $149.19 | 2022-2024 | Fanapt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $128.69 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $102.95 | 2021 | |
| Axsome Therapeutics, INC. | $87.28 | 2022-2024 | Auvelity |
| Bausch Health US, LLC | $85.69 | 2022-2024 | Aplenzin |
| Janssen Pharmaceuticals, INC | $78.23 | 2022-2023 | Spravato |
| Almatica Pharma LLC | $30.29 | 2022 | |
| Biogen, INC. | $24.60 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $23.80 | 2024 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $18.35 | 2023 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.